Remicade in the Treatment of Patients With Active Ankylosing Spondylitis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01850121|
Recruitment Status : Completed
First Posted : May 9, 2013
Last Update Posted : August 9, 2016
|Condition or disease||Intervention/treatment|
|Ankylosing Spondylitis||Drug: Infliximab|
|Study Type :||Observational|
|Actual Enrollment :||19 participants|
|Official Title:||Remicade in the Treatment of Patients With Active Ankylosing Spondylitis|
|Study Start Date :||January 2003|
|Actual Primary Completion Date :||May 2008|
|Actual Study Completion Date :||May 2008|
Patients with active AS defined as BASDAI score above 4 and no exclusion criteria were consecutively included in this single-armed unblinded trial.
5 mg/kg every 6 weeks during the first year and 3 mg/kg every 8 weeks during the second year. Concomitant treatment with methotrexate 7.5 mg/week.
Other Name: Remicade
- Bath AS disease activity score (BASDAI) [ Time Frame: 16 weeks ]The proportion of responders at week 16 defined as a reduction of 50% and/or 2 units improvement from baseline of Bath AS disease activity score (BASDAI)
Biospecimen Retention: Samples Without DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01850121
|Sahlgrenska University Hospital|
|Gothenburg, Sweden, S-413 45|
|Principal Investigator:||Boel Morck, MD||Sahlgrenska University Hospital, Sweden|